Compare Amphastar Pharmaceuticals Inc (AMPH) vs Gap Inc (GAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Gap Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Gap Inc trades at $19.41 (market cap $7.01B). The key difference: Gap Inc is far larger — about 8.5× Amphastar Pharmaceuticals Inc's market cap, and Gap Inc pays a 3.6% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | GAP | |
|---|---|---|
Market Cap | $826.08M | $7.01B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $29.13 |
52-Week Low | $16.87 | $18.35 |
Enterprise Value | $1.22B | $10.09B |
Dividend Yield | — | 3.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Gap Inc. (GAP) trades at $19.46, up 3.24% today, with a bearish technical outlook but attractive valuation metrics including a P/E of 7.72 and P/S of 0.48. Recent earnings show mixed results with a Q1 2026 beat but a Q4 2025 miss. The company demonstrates strong profitability with a net income margin of 6.25% and ROE of 27.58%, supported by positive operating cash flow of $1.49 billion in 2025. News highlights include ongoing investigations by law firms and digital transformation efforts.
The stock presents a value opportunity with a consensus price target of $27.00, implying significant upside, but faces risks from legal scrutiny and competitive pressures. Analyst sentiment is mixed with 39.58% buy ratings, while technical indicators suggest near-term weakness. Revenue growth remains modest, projected at $15.4 billion for 2026, with earnings stability key to unlocking value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
